Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Tech Stocks (FAANGs, TSLA, PLUG, NVDA) Sing The Blues Monday, But 6 Sectors & Dow 30 Advance

By John F. Heerdink, Jr.

Monday’s trading session seemed a bit heavier than usual as the highly followed tech stocks left investors singing the blues. The tech heavy Nasdaq shaved off a cool 2.46% today closing at 13,533.05. The FAANG’s ended lower across the board as follows: Apple (AAPL) shares closed at $126, -2.98%, Amazon (AMZN) ($3,189.74, -2.13%), Alphabet (GOOG) closed at $2,064.88,-1.73%, Facebook (FB) closed at $260.33, -.47%, & Netflix (NFLX) closed at $533.78/share, -1.19%. Tesla also had a not so great day closing at $714.50, -8.55% as negative press hit post the recent Texas winter storm related power outages even though many Tesla owners managed to keep moving with their self-sufficient energy storage system, but many others unfortunately saw their charging costs go through the roof (normal charge of $25 reportedly blew up to $900 as spot electricity speed to $9000 per megawatt-hour due to the Texas’ real-time auction system). Shares of the leading provider of hydrogen engines and fueling solutions enabling e-mobility Plug Power (PLUG) closed at $48.60, -13.04%. Plug reports Q4 2020 and Year end results on February 25th. NVIDIA Corporation (NVDA) achieved a new all-time high of $614.90 last week prior to closing at $574.23, -3.82% on Friday. NVDA has risen greatly during the ongoing “global chip shortage” as their chips power the future of self-driving cars and cloud gaming. The FTC is also investigating their $40 billion acquisition of Arm Ltd. Arm’s tech reportedly is going into chips of billions of devices shipping this year including smartphones, video cameras, hard drives, washing machines, etc. NVDA reports Q4 results for fiscal 2021 after the closing bell tomorrow, Tuesday, Feb 23.

The S&P 500 also closed lower at 3,876.50 (-.77%) despite 6 of the 11 sectors ending in the green. The energy sector led all sectors jumping 3.5% as oil prices rose again to close at $61.63, +4.5% fueled by a combination of reopening steps/hopes and OPEC+ supply restrictions. The Russell 2000 also closed down at 2,251.07 (-.69%) while the Dow 30 was the lone ranger to end in the green today closing at 31,521.69 (+.09%).


The macroeconomic schedule delivered the Conference Board’s Leading Economic Index report which confirmed a rise by .5% month/month in January. Tomorrow, the schedule will deliver the Conference Board’s Consumer Confidence Index report for February, the FHFA Housing Price Index report for February, & the S&P Case-Shiller Home Price Index report for December.

The 2-yr treasury yield closed even at .11%, while the 10-yr treasury yield rose 1 basis point to end at 1.36%. The U.S. Dollar ticked lower to end at 90.12.

Further US economic stimulus is still lingering & is held up by the tight & self promoting grips of our good ‘ole politicians. 


The iShares Nasdaq Biotechnology ETF (IBB) closed at 162.14, -2.51% while the NYSE ARCA Biotech Index(^BTK) closed at 5,940.58, -1.68%. 


The iShares Silver Trust ETF (SLV) closed at $26.27 & the SPDR Gold Shares (GD) closed at $169.51, +1.5%. Silver prices closed at $28.30/oz, +.94. Gold prices closed at 1,812, +$26.

North American Silver and gold producer Hecla Mining Company (HL) closed at $6.90/share, -13.3% on the day after recently establishing a new 52-week high of $8.45 this week. HL’s 52-week range is $1.4 – $8.45. Last week, Hecla announced Q4 and full year 2020 financial and operating results. Phillips S. Baker, Jr., President and CEO of Hecla stated, “The COVID pandemic provided significant challenges to Hecla and the mining industry; however, due to our people and the jurisdictions we operate in, Hecla exceeded the high end of our pre-COVID silver guidance by 1.4 million ounces. We saw modest disruptions in Quebec and Mexico; however, these did not materially impact our business. During the year we refinanced our long-term debt now due in 2028, and through solid free cash flow generation, added cash to the balance sheet, reduced our net debt, and increased dividends. As we look to 2021, we see three significant value drivers. First, with Lucky Friday running at full production, positive results from the work at Casa Berardi, and the continued consistency of Greens Creek, we expect to grow silver production and generate significant free cash flow. Silver production from our United States silver mines is expected to go from 8 million ounces in 2018 to almost 15 million ounces by 2023, further increasing Hecla’s position as the most significant US silver producer. Second, we start the year with the 3rd highest reserves in our history despite disruptions to our planned exploration and definition drilling programs due to COVID‑19, and we expect reserve growth in 2021 from a normal drilling program. Finally, Hecla’s 2021 exploration program is following up on high-grade intercepts that have the potential to expand existing or develop new high-quality deposits in some of the world’s best mining jurisdictions. Examples of this are Midas’ Green Racer Sinter target where we have made a multi-ounce gold discovery in a never before drilled target and at San Sebastian’s El Bronco vein where we are seeing high-grade over significant widths.”

I recently hosted a Tribe Public Webinar Presentation and Q&A Event last week with Phillips S. Baker, Jr., President, and CEO of Hecla Mining Company (NYSE: HL) where we discussed The Silver Squeeze” while addressing questions from the Tribe and offering valuable insights on silver prices throughout history and the recent volatility that helped move silver related stocks and the ETF SLV. Please view it by clicking here.  


  • Shares of next generation of gene silencing therapy firm NeuBase Therapeutics (NBSE) closed trading at $10.46, -2.06% after recently reaching a new all-time high of $12.89. Recently, Neubase reported its financial results for the three-month period ended December 31, 2020. Review the story here.
    • Oppenheimer’s analyst Hartaj Singh recently reiterated his OUTPERFORM Rating and his Price Target of $17. 
    • Recently, NeuBase announced the execution of a binding agreement to acquire infrastructure, programs and intellectual property for several peptide-nucleic acid (PNA) scaffolds from Vera Therapeutics, formerly known as TruCode Gene Repair, Inc. The technology has demonstrated the ability to resolve disease in genetic models of several human indications. The acquisition was reported to bolster NeuBase’s capabilities and reinforces the Company’s position as a leader in the field of genetic medicine. Read the complete story. 
    • NeuBase is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.
    • We expect to see the company to announce an update on its work in Huntington’s Disease and also sign a corporate deal of some kind prior to the end of April 2021 based on recent conversations & expectations of management.

  • Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $100.96/share, -8.37% after recently establishing a new all-time high of $121.16.

    • Fate announced that the Company will host a conference call and live audio webcast on Wednesday, February 24, 2021 at 5:00 p.m. ET to report its fourth quarter and full year 2020 financial results and provide a corporate update. Learn more here. 
    • FATE also recently announced the pricing of an underwritten public offering of ~$432 million at $85.50/share. Jefferies, BofA Securities, SVB Leerink and Barclays acted as joint book-running managers for the offering.

    • We started with Fate over 3 years ago when it was in the $3 range. Fate’s 52-wk range is $16.75- $103.86. 

    • Recently, Fate presented a patient case study from the Company’s Phase 1 clinical trial of FT596, its universal, off-the-shelf, CD19-targeted chimeric antigen receptor (CAR) natural killer (NK) cell product candidate, at the 62nd Annual Society of Hematology Annual Meeting and Exposition and the street loved it. NK cells are the body’s first line of defense against viral infections and cancerous cells with an innate ability to rapidly seek and destroy transformed cells. NK cell therapy has the potential to 1) target multiple pathogenic antigens with measurably more efficient cytotoxicity, 2) be better controlled to reduce risk of cytokine storms and 3) be produced from a variety of sources without relying on patient-specific immune cells. Dr. Wayne Chu, Senior Vice President, Clinical Development of Fate Therapeutics stated, “The safety, pharmacokinetics and clinical activity observed following both the first and second single-dose treatment cycles of FT596 are compelling, especially when considering that the administered cell dose was significantly lower than the recommended cell dose of FDA-approved autologous CD19-targeted CAR T-cell therapies and that the heavily pre-treated patient was refractory to last prior therapy. We are excited the CAR component of FT596 has shown clinical activity at this low dose level, and we continue to enroll patients in dose escalation with FT596 as a monotherapy and in combination with rituximab.”

  • Shares of INVO Bioscience (NASDAQ: INVO), a low float stock,  closed at $3.45/share, -8.49%. INVO has now closed soundly above its 50-day moving average of $3.10 once again & there appears to be a significant gap up to its $5.05 or 200-day moving average.
    • Recently, INVO announced that it has advanced its commercialization efforts into the European fertility market by securing initial orders of INVOcell in Madrid and Barcelona, Spain. INVOcell will initially be available at three separate existing fertility clinics which have placed orders and commenced training. Please read the story here.
    • INVO is a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System. Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.
    • INVO’s Management Issued a letter to shareholders recently that spoke to their key developments and future initiatives that have positioned their product INVOcell® within the severely underserved fertility market. PLEASE read the story here.
    • INVO received BUY Ratings from both Roth Capital ($5 PT) & Collier International Securities ( $5.75 PT) in December, 2020.  ]

  • Shares of Chinook Therapeutics (KDNY), a clinical-stage biotechnology company developing precision medicines for kidney diseases, closed today at $16, +3.16%. Recently, Chinook announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A (LDHA) for primary hyperoxaluria (PH). PH is a group (PH1, PH2 and PH3) of ultra-rare genetic diseases caused by enzyme mutations that result in excess oxalate production in the liver, and in its most severe forms, can lead to end-stage kidney disease at a young age. Inhibition of LDHA with CHK-336 allows for the potential to treat all forms of PH and other disorders arising from excess oxalate, while its liver-targeted tissue distribution profile enables maximal inhibition of liver oxalate production with minimal systemic exposure. Please read the story here.
    • Chinook management will present at the SVB Leerink Global Healthcare Conference on February 24th at 10am ET. 
    • I recently hosted Chinook’s President & CEO Eric Dobmeier at our sister organization Tribe Public’s Presentation and Q&A event, Tuesday, Jan. 26th which you can watch now at Tribe Public YouTube Channel
    • Chinook has well-funded development programs with participation in a $115 million private placement financing concurrent with the close of a merger with Aduro Biotech in Q4 2020 from top-tier healthcare investors including, EcoR1 Capital, OrbiMed Advisors, funds managed by Rock Springs Capital, Fidelity Management and Research Company LLC, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech and others.

  • Shares of Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at $2.93/share, -5.79%.
    • Recently, Atossa’s President and CEO Dr. Steven C. Quay issued his annual Letter to Stockholders highlighting key accomplishments and strategy for 2021. Please view it here.
    • Recently, Atossa announced updated findings following 26 months of Expanded Access (or “compassionate use”) single-patient studies of Atossa’s Endoxifen. “To date, the patient has not had a recurrence of breast cancer, as assessed by clinical breast examination and mammography; has not had treatment-related changes in periodic laboratory blood tests and general clinical examinations; and, the treatment has been well tolerated, including an absence of typical vasomotor symptoms commonly associated with tamoxifen (for example, night sweats and hot flashes), an FDA-approved drug frequently prescribed for breast cancer treatment,” commented Sidney Goldblatt, M.D., Principal Investigator. “This patient, like many breast cancer patients, was reluctant to take tamoxifen because of the well-documented side effects associated with that drug and because she lacked the proper liver enzymes to properly metabolize tamoxifen. We are very encouraged by this patient’s experience with our Endoxifen over the past two years. Her experience serves as a model for ongoing development efforts,” commented Steve Quay, Ph.D., M.D., Atossa’s President and CEO.  Yesterday, I hosted  Tribe Public’s Webinar Presentation and Q&A Event with Steven Quay, MD, PhD, CEO & Founder & Kyle Guse CFO of Atossa Therapeutics (NASDAQ: ATOS) who delivered a presentation titled “The Important Role of COVID-19 Therapeutics In A Post-Vaccine World.” They also addressed Q&A session at the end of the presentation. Please view it here.
    • Recently, Atossa announced that based on substantially positive results achieved with the patients enrolled to date in its Australian open-label Phase 2 clinical study of oral Endoxifen administered in the “window of opportunity” between diagnosis of breast cancer and surgery, Atossa has halted the study and is accelerating its Endoxifen program in the United States. “It is a welcome event to halt an ongoing clinical trial because the results are so overwhelmingly positive,” commented Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer. “Data from the first six patients in our Australian Phase 2 window of opportunity study shows a 74% average reduction in Ki-67, which is a common measure of tumor cell activity, and that at the time of surgery all patients had Ki-67 levels lower than 25%, which is an important threshold to improve long-term survival as identified in studies by others. We believe that additional enrollment will not alter these positive results so we are terminating the study early. This saves at least a year on the development time line allowing us to accelerate clinical development in the Unites States. We look forward to reporting final data from all patients in the study and sharing our continued progress in the development of oral Endoxifen.”
    •  Atossa recently raised ~$81M in gross proceeds affording the company a significant development runway and many more options to be considering. 
    • Atossa is seeking in the near term to get an FDA nod to move into a Phase 2 trial with its nasal spray COVID-19 therapy.

Please review our complete VP Watchlist that includes nine highlighted companies. The pages will allow you to learn more and keep up with these companies daily. 

Also, please make sure that you check out the interesting quotes and selected videos that we have highlighted below. 


Symbol Name Last Price Change % Change

Big Movers

Symbol Name Last Price Change % Change

Bond Markets & US Dollar

Symbol Name Last Price Change % Change

Economic Reports

  • On Monday, the Conference Board’s Leading Economic Index report confirmed a rise by .5% month/month in January.

Agriculture & Energy

Symbol Name Last Price Change % Change

Biotech & Healthcare

Symbol Name Last Price Change % Change

Consumer Goods & Trends

Symbol Name Last Price Change % Change

Financials & Fintech

Symbol Name Last Price Change % Change

Materials & Natural Resources

Symbol Name Last Price Change % Change

Technology & Beyond

Symbol Name Last Price Change % Change

Investing & Inspiration

  1. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  2. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  3. “No Price is too low for a bear or too high for a bull.” — Anonymous
  4. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  5. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  6. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  7. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  8. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  9. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  10. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  11. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  12. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  13. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  14. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  15. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  16. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  17. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  18. “Know what you own, and know why you own it.” – Peter Lynch
  19. “Liquidity is only there when you don’t need it.” -Old Proverb
  20. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  21. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  22. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  23. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  24. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  25. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  26. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  27. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  28. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  29. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  30. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  31. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  32. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  33. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  34. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  35. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  36. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  37. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  38. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  39. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  40. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  41. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger
Symbol Name Last Price Change % Change


Please consider viewing these interesting videos: